Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

May 9, 2014

JobWatch: PhRMA Warns U.S. Could Lose 149,000 Jobs

New report offers ideas from pharma execs for policy changes to thwart potential cuts.

JobWatch: PhRMA Warns U.S. Could Lose 149,000 Jobs

In this regular feature, GEN keeps track of the biotech job market. This month’s JobWatch discusses a new PhRMA report on biopharma jobs in the U.S. [© Maksym Yemelyanov - Fotolia.com]

  • The U.S. stands to lose up to 149,000 jobs over the next decade unless Washington enacts industry-friendlier policies that Pharmaceutical Research and Manufacturers of ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »